Key result
Verapamil increases aliskiren AUC and Cmax ~2-fold without requiring dose adjustment.
Why the study?
Does verapamil alter the pharmacokinetics of aliskiren in healthy participants?
Does verapamil alter the pharmacokinetics of aliskiren in healthy participants?
Coadministration of aliskiren with the moderate ABCB1 inhibitor verapamil increases aliskiren exposure approximately 2-fold, but no dose adjustment is necessary.
Answers are grounded in this paper and cite their sources.
Supports unchanged aliskiren dosing with verapamil; extends pharmacokinetic interaction data in healthy participants.
The authors describe the drug-drug interaction between aliskiren and verapamil in healthy participants. Eighteen participants first received an oral dose of aliskiren 300 mg (highest recommended clinical dose) in period 1. After a 10-day washout period, the participants received verapamil 240 mg/d for 8 days (period 2). On day 8, the participants also received an oral dose of aliskiren 300 mg. Safety and pharmacokinetic analyses were performed during each treatment period. Concomitant administration of a single dose of aliskiren during steady-state verapamil resulted in an increase in plasma concentration of aliskiren. The mean increase in AUC(0-∞), AUC(last), and C(max) was about 2-fold. On day 8, in the presence of aliskiren, AUC(τ,ss) of R-norverapamil, R-verapamil, S-norverapamil, and S-verapamil was decreased by 10%, 16%, 10%, and 25%, respectively. Similarly, the C(max,ss) of R-norverapamil, R-verapamil, S-norverapamil, and S-verapamil was decreased by 13%, 18%, 12%, and 24%, respectively. Aliskiren did not affect the AUC(τ,ss) ratios of R-norverapamil/R-verapamil and S-norverapamil/S-verapamil. Aliskiren administered alone or in combination with verapamil was well tolerated in healthy participants. In conclusion, no dose adjustment is necessary when aliskiren is administered with moderate ABCB1 inhibitors such as verapamil (240 mg/d).
No takes yet. Share an insight, caveat, or question.
Rebello et al. (2010) studied Healthy (n=18). Aliskiren and Verapamil coadministration vs. Aliskiren alone was evaluated on Pharmacokinetics (AUC and Cmax) of aliskiren (about 2-fold increase). Concomitant administration of aliskiren and verapamil resulted in an approximately 2-fold increase in aliskiren AUC and Cmax, though no dose adjustment is necessary.
Synapse has enriched 10 related papers. Consider them for comparative context: